AstraZeneca has announced a major expansion ... spend $2bn to bolster its manufacturing capacity in states including Maryland and Texas as well as on the west coast. This would bring its total ...
AstraZeneca’s expanding footprint in the US includes, among others: A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts; A next generation manufacturing facility for biologics in ...
UK-based biopharmaceutical company AstraZeneca has announced a $3.5bn ... a new biologics manufacturing facility in Maryland and expand specialty manufacturing in Texas. Additionally, it will ...
AstraZeneca made headlines for several reasons on Tuesday ... The investment will also support creation of a new next generation manufacturing facility, focused on biologics, in Maryland as well as ...
The new investments will expand manufacturing sites in Maryland, Texas and California. But AstraZeneca shares have fallen nearly 6% this year, underperforming a near 9% rise in the wider European ...
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
The pact with Mankind Pharma, announced in March 2024, was an exclusive agreement for distribution of budesonide and ...
AstraZeneca’s expanding footprint in the ... Massachusetts A next generation manufacturing facility for biologics in Maryland Cell therapy manufacturing capacity on the West and East Coasts ...
AstraZeneca’s expanding footprint in the US includes, among others: A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts A next generation manufacturing facility for biologics in ...
(Reuters) -Drugmaker AstraZeneca lifted its annual sales and ... The new investments will expand manufacturing sites in Maryland, Texas and California and create 1,000 high-skilled jobs in the ...